NEW YORK, Feb. 07, 2017 -- The Nasdaq Stock Market® (Nasdaq:NDAQ) announced that trading was halted today in Kitov Pharmaceuticals Holdings Ltd. (Nasdaq:KTOV), (Nasdaq:KTOVW) at 09:22:28 Eastern Time for "additional information requested" from the company at a last sale price of $2.55 and $0.89 respectively.
Trading will remain halted until Kitov Pharmaceuticals Holdings Ltd. has fully satisfied Nasdaq’s request for additional information.
For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.
NDAQO
Nasdaq Media Contact: Peter Gau +1.212.231.5475 [email protected]


John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
FDA Approves Mitapivat for Anemia in Thalassemia Patients
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



